CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies.

ABSTRACT:

Purpose of review

Cytomegalovirus (CMV) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (Allo-HSCT). New strategies and methods for prevention and management of CMV infection are urgently needed. We aim to review the new developments in diagnostics, prevention, and management strategies of CMV infection in Allo-HSCT recipients.

Recent findings

The approval of the novel anti-CMV drug letermovir in 2017 has led to an increase in the use of antiviral prophylaxis as a preferred approach for prevention in many centers. Real-world studies have shown efficacy similar to the clinical trial. CMV-specific T cell-mediated immunity assays identify patients with immune reconstitution and predict disease progression. Phase 2 trials

SUBMITTER: Jakharia N 

PROVIDER: S-EPMC8294301 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature